Endophthalmitis from Mycobacterium bovis-bacille Calmette-Guerin after intravesicular bacille Calmette-Guerin injections for bladder carcinoma

American Journal of Ophthalmology

Volumn 128, Issue 5, 1999, Pages 648-650

  Han, Dennis P ^a   Simons, Kenneth B ^a   Tarkanian, Cynthia N ^a   Moretti, Scott T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BCG VACCINE;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CASE REPORT; ENDOPHTHALMITIS; EYE INFLAMMATION; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; VISUAL ACUITY; VITREOUS OPACITY;

EID: 0032731161     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(99)00206-8     Document Type: Article

References (5)

1. Lamm D.L., Stogdill V.D., Stogdill B.J., Crispen R.G. Complications of bacillus Calmette-Guérin immunotherapy in 1,278 patients with bladder cancer. J Urol. 135:1986;272-274.
2. Sokal J.E., Aungst C.W., Han T. Effect of BCG on delayed hypersensitivity responses of patients with neoplastic disease. Int J Cancer. 12:1973;242-249.
3. Sakamoto G.D., Burden J., Fisher D. Systemic bacillus Calmette-Guérin infection after transurethral administration for superficial bladder carcinoma. J Urol. 142:1989;1073-1074.
4. Price G.E. Arthritis and iritis after BCG therapy for bladder cancer. J Rheumatol. 21:1994;564-565.
5. Mutyala S., Dieckert J.P., Papasian C.J. Mycobacterium fortuitum endophthalmitis. Retina. 16:1996;122-124.